問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Others-

Division of Family Medicine

Division of Cardiovascular Diseases

Taichung Veterans General Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

盧澤民Lu, Tse-Min
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧澤民

List

76Cases

2020-11-30 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-01-19 - 2027-10-20

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2020-06-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-05-08 - 2027-07-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2021-09-01 - 2027-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2025-10-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2013-02-15 - 2018-09-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

  • Condition/Disease

    Acute Coronary Syndrome

  • Test Drug

    SAR236553/REGN727

Participate Sites
15Sites

Terminated15Sites

蔡惟全
National Taiwan University Hospital

Division of Cardiovascular Diseases

2010-11-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

  • Condition/Disease

    High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)

  • Test Drug

    RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩
Taipei Veterans General Hospital

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

1 2 3 4 5 6 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB